Related Experiment Video

Updated: Jun 3, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.8K

Targeting KRAS: from metabolic regulation to cancer treatment

Yanyan Shi1, Huiling Zheng2, Tianzhen Wang3,4

  • 1Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, 100191, China.

Molecular Cancer
|January 11, 2025
PubMed

Insights

Targeting metabolic alterations in Kirsten rat sarcoma viral oncogene homolog (KRAS)-driven cancers shows promise. This review details KRAS-regulated metabolic reprogramming and advances in targeted therapies for KRAS-mutant cancers.

Area of Science:

  • Oncology
  • Cancer Metabolism
  • Molecular Biology

Background:

  • The Kirsten rat sarcoma viral oncogene homolog (KRAS) protein is a key driver in oncogenesis, cancer progression, and metastasis.
  • Metabolic alterations are crucial in KRAS-driven cancers, offering therapeutic targets.
  • Acquired treatment resistance necessitates novel therapeutic strategies, including KRAS inhibitors.

Purpose of the Study:

  • To review metabolic reprogramming (glucose, glutamine, lipids) regulated by oncogenic KRAS.
  • To highlight the relationship between KRAS-driven metabolic changes and targeted therapy advancements.
  • To summarize KRAS inhibitor discovery and treatment strategies for specific cancers.

Main Methods:

  • Literature review of metabolic reprogramming in KRAS-driven cancers.
  • Analysis of recent insights into KRAS mutant-driven metabolic mechanisms.
  • Focus on advances in KRAS inhibitor discovery and clinical trials.

Main Results:

  • Oncogenic KRAS extensively reprograms glucose, glutamine, and lipid metabolism.
  • KRAS mutations are intricately linked to specific metabolic vulnerabilities.
  • Significant progress has been made in developing KRAS inhibitors and targeted therapies.

Conclusions:

  • Understanding KRAS-mediated metabolic reprogramming is vital for effective cancer treatment.
  • Targeted therapies, including KRAS inhibitors, show potential in treating KRAS-mutant cancers.
  • Further research into metabolic mechanisms and therapeutic strategies is crucial for overcoming treatment resistance.
Keywords:
Cancer metabolismKRAS inhibitorsKRAS-driven cancersMetabolic reprogramming

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.6K
Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

5.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K